Avid Bioservices Inc (CDMO)

[pphmtoolong]

Peregrine's multi-faceted approach to bringing bavituximab to commercial success is firing on all twelve cylinders.

Sunrise will hit important milestones with full enrollment and early look-ins in the next months.

BMS and AstraZeneca are showing strong interest as shown by their clinical collaborations with Peregrine.

The contracted research at MSK will increase Bavi's credibility. Particularly as MSK will investigate Bavi's synergy with the latest immune therapy products from the BPs.

Avid is expanding rapidly to support Bavi's commercial launch and to satisfy increasing demand from third party customers as confirmed by the growing contract backlog.

The critics here continue to snipe away but the quality of their arguments just gets lamer and lamer. The volume is going up, but the content is cratering.

The next few months look very promising. A major partnership could occur at any time.

Success is still uncertain, but IMO the likelihood of success is at an all time high. Maybe we will see that $16 per share price again.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul